Novo Nordisk seen rising as Wegovy pill, Q3 profit beat forecasts

Novo Nordisk A/S

04/11/2026 07:47

** Shares in Novo Nordisk NOVOb.CO are seen rising around 3-4% after the Danish drugmaker posted better-than-expected Q3 results and hiked its full-year sales and profit outlook
** Jefferies says favourable pricing and rebate adjustments boosted quarterly sales, adding that injectable Wegovy would have missed its estimates without this benefit
** Novo added finance chief Karsten Munk Knudsen will leave the company at the end of December, to be replaced by Galderma CFO Luigi La Corte, a change Jefferies says could spark a debate among investors


($1 = 6.6544 Danish crowns)

 (Reporting by Jesus Calero)
 ((jesus.calero@thomsonreuters.com))